| 1 |
33297669 |
10.3324/haematol.2020.267294 |
2022 |
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. |
MYC |
| 2 |
33779481 |
10.1080/01676830.2021.1904426 |
2022 |
Double-hit and triple-hit high-grade B-cell lymphoma of the ocular adnexa. |
MYC |
| 3 |
33782541 |
10.1038/s41401-021-00644-1 |
2022 |
SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma. |
MYC |
| 4 |
33908607 |
10.1182/blood.2020007932 |
2022 |
MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress. |
MYC |
| 5 |
34131801 |
10.1007/s00432-021-03691-7 |
2022 |
Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma. |
MYC |
| 6 |
34162177 |
10.3324/haematol.2020.267096 |
2022 |
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma. |
MYC |
| 7 |
34162179 |
10.3324/haematol.2021.278743 |
2022 |
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas. |
MYC |
| 8 |
34219494 |
10.1177/00031348211029854 |
2022 |
Burkitt Lymphoma Presenting as Perforated Appendicitis. |
MYC |
| 9 |
34289655 |
10.3324/haematol.2021.278638 |
2022 |
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. |
MYC |
| 10 |
34304248 |
10.1038/s41375-021-01347-6 |
2022 |
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. |
MYC |
| 11 |
34359075 |
10.1182/blood.2021012805 |
2022 |
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice. |
MYC |
| 12 |
34392269 |
10.1097/PAS.0000000000001750 |
2022 |
Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity. |
MYC |
| 13 |
34456240 |
10.1097/PAI.0000000000000967 |
2022 |
Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting. |
MYC |
| 14 |
34471258 |
10.1038/s41416-021-01538-z |
2022 |
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. |
MYC |
| 15 |
34472720 |
10.1002/cnr2.1545 |
2022 |
Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement. |
MYC |
| 16 |
34476551 |
10.1007/s00259-021-05498-7 |
2022 |
Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. |
MYC |
| 17 |
34493477 |
10.1016/j.clml.2021.07.017 |
2022 |
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. |
MYC |
| 18 |
34510996 |
10.1080/10428194.2021.1975189 |
2022 |
<i>BCL2</i> translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival. |
MYC |
| 19 |
34519021 |
10.1111/bjh.17815 |
2022 |
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. |
MYC |
| 20 |
34525177 |
10.1182/blood.2020008374 |
2022 |
Defining and treating high-grade B-cell lymphoma, NOS. |
MYC |
| 21 |
34528662 |
10.1093/ajcp/aqab105 |
2022 |
MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma. |
MYC |
| 22 |
34535296 |
10.1016/j.pathol.2021.06.121 |
2022 |
High-grade B-cell lymphoma with concurrent expression of CD5 and cyclin D1 and MYC rearrangement. |
MYC |
| 23 |
34536035 |
10.1111/cup.14135 |
2022 |
Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee. |
MYC |
| 24 |
34559466 |
10.1111/ijlh.13709 |
2022 |
Discordant high-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a pericardial effusion. |
MYC |
| 25 |
34601571 |
10.1182/blood.2021013156 |
2022 |
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. |
MYC |
| 26 |
34608246 |
10.1038/s41379-021-00909-4 |
2022 |
Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. |
MYC |
| 27 |
34612761 |
10.1080/10428194.2021.1986218 |
2022 |
Plasmablastic lymphomas show restricted EBV latency profile and <i>MYC</i> gene aberrations. |
MYC |
| 28 |
34617271 |
10.1111/bjh.17874 |
2022 |
Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. |
MYC |
| 29 |
34632715 |
10.1002/1878-0261.13115 |
2022 |
Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. |
MYC |
| 30 |
34637146 |
10.1111/his.14585 |
2022 |
EBV<sup>+</sup> high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. |
MYC |
| 31 |
34654055 |
10.1182/bloodadvances.2021006034 |
2022 |
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. |
MYC |
| 32 |
34668039 |
10.1007/s00262-021-03057-5 |
2022 |
CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein-Barr virus genes. |
MYC |
| 33 |
34668583 |
10.1002/eji.202149355 |
2022 |
MALT1 protease function in regulatory T cells induces MYC activity to promote mitochondrial function and cellular expansion. |
MYC |
| 34 |
34669156 |
10.1007/s11684-021-0877-y |
2022 |
Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia. |
MYC |
| 35 |
34688842 |
10.1016/j.canlet.2021.10.022 |
2022 |
Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. |
MYC |
| 36 |
34698964 |
10.1007/s10637-021-01196-1 |
2022 |
FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells. |
MYC |
| 37 |
34706126 |
10.1111/cas.15179 |
2022 |
High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma. |
MYC |
| 38 |
34711640 |
10.1158/2159-8290.CD-21-0551 |
2022 |
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. |
MYC |
| 39 |
34714908 |
10.1182/bloodadvances.2021005486 |
2022 |
Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. |
MYC |
| 40 |
34727403 |
10.1111/pin.13182 |
2022 |
AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. |
MYC |
| 41 |
34727830 |
10.1080/10428194.2021.1998480 |
2022 |
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma. |
MYC |
| 42 |
34728235 |
10.1016/j.bbamcr.2021.119168 |
2022 |
DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication. |
MYC |
| 43 |
34739417 |
10.1097/PAS.0000000000001830 |
2022 |
Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma. |
MYC |
| 44 |
34764434 |
10.1038/s41379-021-00962-z |
2022 |
BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. |
MYC |
| 45 |
34788985 |
10.3324/haematol.2021.279631 |
2022 |
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing. |
MYC |
| 46 |
34842019 |
10.1080/10428194.2021.2008383 |
2022 |
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? |
MYC |
| 47 |
34861448 |
10.1016/j.wneu.2021.11.108 |
2022 |
Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma. |
MYC |
| 48 |
34872752 |
10.1016/j.pathol.2021.09.009 |
2022 |
EBV-positive low-grade follicular lymphoma transforming to EBV-negative high-grade B-cell lymphoma with MYC and BCL2 rearrangements. |
MYC |
| 49 |
34875555 |
10.1016/j.leukres.2021.106769 |
2022 |
MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1). |
MYC |
| 50 |
34882582 |
10.1172/JCI153283 |
2022 |
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. |
MYC |
| 51 |
34903527 |
10.1101/gr.275911.121 |
2022 |
Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers. |
MYC |
| 52 |
34910327 |
10.1111/jop.13269 |
2022 |
Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases. |
MYC |
| 53 |
34951009 |
10.1111/bjh.17971 |
2022 |
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. |
MYC |
| 54 |
34954522 |
10.1016/j.bbrc.2021.12.063 |
2022 |
The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation. |
MYC |
| 55 |
34962105 |
10.1002/dc.24922 |
2022 |
Primary thyroid high-grade B-cell lymphoma with MYC and BCL2 rearrangements in Hashimoto's thyroiditis. |
MYC |
| 56 |
34971957 |
10.1016/j.bbrc.2021.12.078 |
2022 |
CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. |
MYC |
| 57 |
34975070 |
10.4103/aja2021114 |
2022 |
Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells. |
MYC |
| 58 |
34980601 |
10.1158/1078-0432.CCR-21-2949 |
2022 |
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. |
MYC |
| 59 |
34983615 |
10.1186/s13046-021-02226-9 |
2022 |
SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma. |
MYC |
| 60 |
34997652 |
10.1111/ejh.13736 |
2022 |
Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma. |
MYC |
| 61 |
35013138 |
10.1038/s41420-021-00622-w |
2022 |
Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis. |
MYC |
| 62 |
35019715 |
10.1128/jvi.01941-21 |
2022 |
Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties. |
MYC |
| 63 |
35020836 |
10.1182/blood.2021012077 |
2022 |
Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL. |
MYC |
| 64 |
35022408 |
10.1038/s41467-021-27704-8 |
2022 |
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma. |
MYC |
| 65 |
35030628 |
10.1182/bloodadvances.2021005948 |
2022 |
Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. |
MYC |
| 66 |
35031886 |
10.1186/s43556-021-00066-9 |
2022 |
Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. |
MYC |
| 67 |
35036912 |
10.1177/2632010X211070774 |
2022 |
Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow. |
MYC |
| 68 |
35045798 |
10.1080/10428194.2021.2024821 |
2022 |
High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma. |
MYC |
| 69 |
35046056 |
10.1158/1078-0432.CCR-21-3617 |
2022 |
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. |
MYC |
| 70 |
35054466 |
10.3390/life12010073 |
2022 |
The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma. |
MYC |
| 71 |
35069971 |
10.1155/2022/3334522 |
2022 |
Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma. |
MYC |
| 72 |
35075986 |
10.1080/10428194.2021.2008381 |
2022 |
RNA-binding proteins as drivers of AML and novel therapeutic targets. |
MYC |
| 73 |
35078195 |
10.1159/000520723 |
2022 |
The Expression of the RUVBL1 Component of the R2TP Complex Correlates with Poor Prognosis in DLBCL. |
MYC |
| 74 |
35082399 |
10.1038/s41417-021-00415-4 |
2022 |
CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma. |
MYC |
| 75 |
35091546 |
10.1038/s41420-022-00833-9 |
2022 |
Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma. |
MYC |
| 76 |
35091678 |
10.1038/s41388-021-02162-0 |
2022 |
An mRNA expression-based signature for oncogene-induced replication-stress. |
MYC |
| 77 |
35114276 |
10.1016/j.gene.2022.146234 |
2022 |
Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma. |
MYC |
| 78 |
35123209 |
10.1016/j.esmoop.2021.100337 |
2022 |
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients. |
MYC |
| 79 |
35125708 |
10.1007/s12288-021-01427-8 |
2022 |
Comparison Between CHOP and DAEPOCH with or Without Rituximab in Adult High Grade B Cell Lymphoma, Not Otherwise Specified; A Retrospective Study From a Tertiary Cancer Hospital in South India. |
MYC |
| 80 |
35126914 |
10.1155/2022/2842066 |
2022 |
Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis. |
MYC |
| 81 |
35132576 |
10.1007/s12519-022-00517-5 |
2022 |
ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma. |
MYC |
| 82 |
35135797 |
10.1136/bcr-2021-246687 |
2022 |
Burkitt lymphoma: interpreting FISH testing for <i>MYC</i> gene rearrangements. |
MYC |
| 83 |
35139388 |
10.1016/j.celrep.2022.110338 |
2022 |
The spliceosome component Usp39 controls B cell development by regulating immunoglobulin gene rearrangement. |
MYC |
| 84 |
35145347 |
10.1016/j.jsps.2021.12.009 |
2022 |
Reposition of the anti-inflammatory drug diacerein in an <i>in-vivo</i> colorectal cancer model. |
MYC |
| 85 |
35149590 |
10.1158/0008-5472.CAN-21-1168 |
2022 |
Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. |
MYC |
| 86 |
35152630 |
10.3760/cma.j.cn112151-20210826-00604 |
2022 |
[Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements]. |
MYC |
| 87 |
35167621 |
10.1371/journal.pone.0263980 |
2022 |
Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature. |
MYC |
| 88 |
35169547 |
10.4102/ajlm.v11i1.1355 |
2022 |
Extranodal presentation of a lymphoma with precursor B-cell phenotype and translocation t(8;14) in South Africa. |
MYC |
| 89 |
35171885 |
10.1097/DAD.0000000000002077 |
2022 |
A Case of CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type Secondary to Chronic Lymphedema. |
MYC |
| 90 |
35173274 |
10.1038/s41375-022-01516-1 |
2022 |
Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. |
MYC |
| 91 |
35174018 |
10.7759/cureus.21208 |
2022 |
A Conservative Approach to the Treatment of a Rare Case of Cervical Spine Double Expressor Diffuse Large B-cell Lymphoma: A Case Report. |
MYC |
| 92 |
35183824 |
10.1016/j.prp.2022.153804 |
2022 |
Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma. |
MYC |
| 93 |
35185889 |
10.3389/fimmu.2022.797244 |
2022 |
Calcium Signaling Is Impaired in PTEN-Deficient T Cell Acute Lymphoblastic Leukemia. |
MYC |
| 94 |
35198451 |
10.3389/fonc.2022.834288 |
2022 |
Prognostic Value of Radiomic Features of <sup>18</sup>F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells. |
MYC |
| 95 |
35205272 |
10.3390/genes13020227 |
2022 |
The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. |
MYC |
| 96 |
35216159 |
10.3390/ijms23042044 |
2022 |
IBtkα Activates the β-Catenin-Dependent Transcription of <i>MYC</i> through Ubiquitylation and Proteasomal Degradation of GSK3β in Cancerous B Cells. |
MYC |
| 97 |
35223507 |
10.3389/fonc.2022.824632 |
2022 |
<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS. |
MYC |
| 98 |
35231992 |
10.3760/cma.j.issn.0253-2727.2022.01.009 |
2022 |
[MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis]. |
MYC |
| 99 |
35245453 |
10.1016/j.molcel.2022.02.015 |
2022 |
How to resist Notch-targeted T-leukemia therapy: Lineage- and MYC enhancer switch. |
MYC |
| 100 |
35246617 |
10.1038/s41388-022-02257-2 |
2022 |
Alcohol-driven metabolic reprogramming promotes development of RORγt-deficient thymic lymphoma. |
MYC |
Datasets
Models
